JP2015504870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504870A5 JP2015504870A5 JP2014547526A JP2014547526A JP2015504870A5 JP 2015504870 A5 JP2015504870 A5 JP 2015504870A5 JP 2014547526 A JP2014547526 A JP 2014547526A JP 2014547526 A JP2014547526 A JP 2014547526A JP 2015504870 A5 JP2015504870 A5 JP 2015504870A5
- Authority
- JP
- Japan
- Prior art keywords
- angiotensin
- disorder
- derivative
- analog
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 claims 2
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 1
- 230000003176 fibrotic Effects 0.000 claims 1
Claims (1)
- 処置を必要とする被験体において線維症性疾患、障害、または状態を処置するまたは予防するための組成物であって、アンジオテンシン（１−７）またはそのアナログもしくは誘導体を含む、組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576673P | 2011-12-16 | 2011-12-16 | |
| US61/576,673 | 2011-12-16 | ||
| US201161579936P | 2011-12-23 | 2011-12-23 | |
| US61/579,936 | 2011-12-23 | ||
| PCT/US2012/069930 WO2013090833A1 (en) | 2011-12-16 | 2012-12-14 | Angiotensins for treatment of fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504870A JP2015504870A (ja) | 2015-02-16 |
| JP2015504870A5 true JP2015504870A5 (ja) | 2016-02-12 |
Family
ID=48613248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547526A Pending JP2015504870A (ja) | 2011-12-16 | 2012-12-14 | 線維症を処置するためのアンジオテンシン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150057216A1 (ja) |
| EP (1) | EP2790716A4 (ja) |
| JP (1) | JP2015504870A (ja) |
| KR (1) | KR20150028761A (ja) |
| CN (1) | CN104302305A (ja) |
| AU (1) | AU2012351939A1 (ja) |
| BR (1) | BR112014014674A2 (ja) |
| CA (1) | CA2859573A1 (ja) |
| WO (1) | WO2013090833A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 |
| KR20160016872A (ko) * | 2013-05-24 | 2016-02-15 | 타릭스 파마슈티컬스 엘티디. | 마르팡 증후군 및 관련 장애의 치료에서의 안지오텐신 펩티드 |
| JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
| SG11201609593RA (en) * | 2014-05-16 | 2016-12-29 | Ultrast Inc | Phase-shifting formulations |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| US9796759B2 (en) | 2014-07-21 | 2017-10-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides and methods for using and producing the same |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| SG11201808478RA (en) | 2015-07-30 | 2018-10-30 | Univ Monash | Fibrotic treatment |
| WO2017066552A1 (en) | 2015-10-14 | 2017-04-20 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2017218623A1 (en) * | 2016-06-14 | 2017-12-21 | Tarix Orphan Llc | Methods and compositions for the treatment of epidermolysis bullosa |
| EP3655008A4 (en) | 2017-07-17 | 2021-04-07 | Monash University | ANGIOTENSIN RECEPTOR AGONISTS AND THEIR USES |
| EP4085921A1 (en) * | 2021-05-04 | 2022-11-09 | CU-Pharmaceuticals UG | Angiotensin-(1-7) in the treatment of sars-cov related diseases |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU755225B2 (en) * | 1997-12-12 | 2002-12-05 | University Of Southern California | Wound healing compositions |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| US7064127B2 (en) * | 2003-12-19 | 2006-06-20 | Mount Sinai School Of Medicine Of New York University | Treatment of hepatic fibrosis with imatinib mesylate |
| EP2163259B1 (en) * | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
-
2012
- 2012-12-14 AU AU2012351939A patent/AU2012351939A1/en not_active Abandoned
- 2012-12-14 WO PCT/US2012/069930 patent/WO2013090833A1/en active Application Filing
- 2012-12-14 JP JP2014547526A patent/JP2015504870A/ja active Pending
- 2012-12-14 CN CN201280069856.3A patent/CN104302305A/zh active Pending
- 2012-12-14 BR BR112014014674A patent/BR112014014674A2/pt not_active Application Discontinuation
- 2012-12-14 KR KR20147019878A patent/KR20150028761A/ko not_active Application Discontinuation
- 2012-12-14 EP EP12857486.0A patent/EP2790716A4/en not_active Withdrawn
- 2012-12-14 CA CA2859573A patent/CA2859573A1/en not_active Abandoned
- 2012-12-14 US US14/365,565 patent/US20150057216A1/en not_active Abandoned
-
2015
- 2015-11-23 US US14/948,985 patent/US20160074466A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504870A5 (ja) | ||
| JP2015503422A5 (ja) | ||
| JP2014530840A5 (ja) | ||
| JP2012143233A5 (ja) | ||
| JP2013525942A5 (ja) | ||
| JP2015528502A5 (ja) | ||
| JP2014520248A5 (ja) | ||
| BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
| JP2016515522A5 (ja) | ||
| JP2013514381A5 (ja) | ||
| JP2011170856A5 (ja) | ||
| BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
| JP2009039101A5 (ja) | ||
| BRPI0917567A2 (pt) | tratamento de doença respiratória | |
| JP2015525757A5 (ja) | ||
| JP2014526140A5 (ja) | ||
| ZA201402907B (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| EP2699584A4 (en) | CYCLIC PEPTIDE FROM NONOMURAEA SP., METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MICRO-BACTERIA-INFLAMMATED DISEASES THEREWITH | |
| BRPI0906606A2 (pt) | Tratamento terapêutico para condições do pulmão. | |
| JP2013536184A5 (ja) | ||
| JP2013231052A5 (ja) | ||
| BR112014009789A2 (pt) | cisteamina no tratamento da doença fibrótica | |
| DK2931296T3 (da) | Sygdomsbehandling, der involverer mucin |